Hürriyet - Swiss pharmaceutical company Novartis relies on Turkey for easy access to markets in the Middle East, Central Asia and Africa. Turkey will be the regional base for the drug maker, which is planning to establish a production plant in the country, according to company officials on a visit to Ankara.
A delegation from Switzerland, consisting of the country’s Minister of Economy Johann Schneider-Ammann and representatives from leading Swiss companies met with Turkey’s Minister of Science, Industry and Technology, Nihat Ergun in the Turkish capital. In the meeting, Novartis Board of Directors member Alexandre F. Jetzer Chung said that Turkey has the potential to become a healthcare center for North Africa, replacing Egypt. Stating that Novartis has plans to invest in a production plant in Turkey, Chung added that the country is considered as a gateway to the Middle East, Central Asia and Africa.
The visiting Minister Schneider-Ammann also praised Turkey’s gateway status to other markets, noting that there are over 600 Swiss companies operating in the country.